The question is does Dr. JL have a friend in the NIH to go to bat for us or is this a pay to play deal. I tried to introduce LL to the NIH through my UCLA connection two years ago but we all know the FDA history with our management back then. Let's hope that has changed. They kept us out for 2 years.
Remember in 2019, the FDA was embarrassed by revelations that officials responsible for opioid approvals were taking part in “pay to play” schemes in which manufacturers paid to attend meetings to draw up the criteria for approving prescription narcotics.